P/E ratio for Insulet (PODD)
P/E ratio as of June 2024 (TTM): 120
According to Insulet's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 119.622. At the end of 2022 the company had a P/E ratio of > 1000.
P/E ratio history for Insulet from 2007 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | > 1000 | 263.54% |
| 2021 | > 1000 | -50.22% |
| 2020 | > 1000 | 144.34% |
| 2019 | 951 | -28.06% |
| 2018 | > 1000 | -981.33% |
| 2017 | -150 | 103.03% |
| 2016 | -73.9 | 154.03% |
| 2015 | -29.1 | -41.28% |
| 2014 | -49.5 | 10.8% |
| 2013 | -44.7 | 127.5% |
| 2012 | -19.6 | 2.26% |
| 2011 | -19.2 | 90.9% |
| 2010 | -10.1 | 71.27% |
| 2009 | -5.88 | 161.86% |
| 2008 | -2.24 | 147.98% |
| 2007 | -0.9050 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.4 | -91.26% | 🇺🇸 USA |
 Abbott Laboratories ABT | 35.5 | -70.33% | 🇺🇸 USA |
 Medtronic MDT | 29.6 | -75.29% | 🇮🇪 Ireland |
 Eli Lilly LLY | 167 | 39.29% | 🇺🇸 USA |
 Tandem Diabetes Care
TNDM | -12.4 | -110.39% | 🇺🇸 USA |
 ICU Medical
ICUI | -56.9 | -147.53% | 🇺🇸 USA |
 DexCom DXCM | 113 | -5.90% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.